Of particular relevance to this task, he was a member of the Steering Committee and the Principal Inves- tigator of the Utah Clinical Center Network in the Systolic Blood Pressure Intervention Trial (SPRINT) sponsored by the NIH. Consultancy: Amgen, Bard, Boehringer Ingelheim, Calliditas, Tricida, and UpToDate Grant/research support: National Institutes of Health for SPRINT* *Monies paid to institution. Johannes F.E. Mann, MD (Work Group Co-Chair), is a professor of medicine at the University of Erlangen-N rnberg, Erlangen, Germany, and head of the KfH Kidney Centre, Munich, Germany. He is also an international scholar at the Population Health Research Institute, McMaster University, Hamilton, Can- ada. He is board-certi ed in internal medicine, nephrology, intensive care, and pharmacology. His work focused initially on the physiology of the RAS in experimental animals and later on the role of this system in the diseases of the kidney and the heart. From there, his interest moved to the treatment of progressive kidney dis- eases. The latter included steering, adjudication, and data safety monitoring board memberships in outcome trials, namely AIPRI, HOPE, MICRO-HOPE, HOPE-TOO, RENAL-ONTARGET, RENAL-TRANSCEND, ASCEND, DIABHYCAR, ORIGIN, LEADER, SONAR, SOUL, FLOW, DAPA-CKD. His scienti c work includes about 270 original papers. Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius Medical Care, Novo Nordisk, and Vifor Fresenius Medical Care Renal Pharma Grant/research support: Boehringer Ingelheim, Canadian Institutes Health Research, European Union, Idorsia, Novo Nordisk, Sandoz, and Sano Speaker bureaus: AstraZeneca, B. Braun, Fresenius Medical Care, Novartis, Novo Nordisk, and Roche Tara I. Chang, MD, MS, is an associate professor of medicine, division chief, and director of clinical research in the Division of Nephrology at Stanford University School of Medicine in Palo Alto, CA, USA. 